CRK SH3N Domain Diminishes Cell Invasiveness of Non-Small Cell Lung Cancer

Gholam H Pezeshkpour1, Farhad Moatamed, Michael Lewis

  • 1Department of Pathology, West Los Angeles VA, Los Angeles, CA, USA.

Genes & Cancer
|October 30, 2013
PubMed

Insights

The CRK-SH3N domain can reduce non-small cell lung cancer (NSCLC) cell invasiveness and malignant phenotype. This adaptor protein domain offers a potential therapeutic strategy to decrease NSCLC metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • CRK (c-Crk) adaptor protein regulates oncogenic signaling pathways.
  • CRK expression and phosphorylation impact non-small cell lung cancer (NSCLC) cell invasiveness.
  • Targeting CRK signaling may offer therapeutic interventions for NSCLC.

Purpose of the Study:

  • To investigate the therapeutic potential of CRK protein domains in NSCLC.
  • To determine if CRK domains can interrupt CRK signaling and influence NSCLC cell behavior.
  • To evaluate the effects of CRK-SH2 and CRK-SH3N domains on NSCLC cell lines.

Main Methods:

  • Overexpression of CRK-SH2 and CRK-SH3N domains in H157, Rh2, and A549 NSCLC cells.
  • Assessment of cellular morphology, motility, and invasiveness.
  • Analysis of the interaction between CRK-II and DOCK180.

Main Results:

  • CRK-SH3N domain expression induced and enhanced epithelial morphology in NSCLC cells.
  • CRK-SH3N domain significantly reduced the motility and invasiveness of A549 and H157 cells.
  • CRK-SH3N domain expression disrupted the CRK-II and DOCK180 interaction.

Conclusions:

  • The CRK-SH3N domain can modulate the malignant phenotype of NSCLC cells.
  • CRK-SH3N domain expression shows potential in reducing the metastatic capacity of NSCLC.
  • CRK protein domains represent promising therapeutic tools for NSCLC treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K